ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells $39,368.00 in Stock

Key Points

• ANI Pharmaceuticals VP Meredith Cook sold 400 shares of the company's stock at an average price of $98.42, totaling $39,368, which decreased her ownership by 0.52%.
• The company's stock recently traded up by 1.1%, reaching $98.81, with a twelve-month high of $99.50 and a market capitalization of $2.14 billion.
• ANI Pharmaceuticals reported $1.80 earnings per share, exceeding analyst expectations, with a quarterly revenue increase of 53.2% year-over-year.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 400 shares of the company's stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $98.42, for a total value of $39,368.00. Following the sale, the vice president directly owned 76,074 shares in the company, valued at approximately $7,487,203.08. This represents a 0.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Meredith Cook also recently made the following trade(s):

• On Wednesday, August 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $88.87, for a total transaction of $35,548.00.
• On Monday, July 14th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $64.88, for a total transaction of $25,952.00.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock traded down $0.69 during trading hours on Friday, reaching $96.79. The company's stock had a trading volume of 346,251 shares, compared to its average volume of 380,949. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $99.50. The company's 50 day simple moving average is $82.71 and its 200 day simple moving average is $70.98. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.96 and a current ratio of 2.54. The stock has a market cap of $2.10 billion, a P/E ratio of -125.70 and a beta of 0.63.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.42 by $0.38. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The firm had revenue of $211.37 million for the quarter, compared to analysts' expectations of $187.18 million. During the same quarter last year, the company posted $1.02 earnings per share. ANI Pharmaceuticals's revenue was up 53.2% on a year-over-year basis. As a group, analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Analyst Ratings Changes

ANIP has been the topic of several analyst reports. Guggenheim increased their target price on ANI Pharmaceuticals from $86.00 to $114.00 and gave the stock a "buy" rating in a research report on Monday, September 8th. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 16th. Truist Financial lifted their price objective on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a "hold" rating in a research report on Monday, August 11th. Zacks Research upgraded shares of ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 21st. Finally, Piper Sandler restated an "overweight" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, ANI Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $93.00.

Institutional Trading of ANI Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Principal Financial Group Inc. lifted its position in ANI Pharmaceuticals by 68.3% in the first quarter. Principal Financial Group Inc. now owns 157,798 shares of the specialty pharmaceutical company's stock worth $10,565,000 after purchasing an additional 64,021 shares during the period. Allspring Global Investments Holdings LLC raised its stake in shares of ANI Pharmaceuticals by 53.3% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,949 shares of the specialty pharmaceutical company's stock worth $599,000 after buying an additional 3,112 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of ANI Pharmaceuticals by 1.0% in the first quarter. Invesco Ltd. now owns 199,567 shares of the specialty pharmaceutical company's stock valued at $13,361,000 after buying an additional 2,022 shares during the period. GAMMA Investing LLC boosted its stake in ANI Pharmaceuticals by 163.8% during the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock valued at $95,000 after buying an additional 881 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in ANI Pharmaceuticals by 0.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 238,377 shares of the specialty pharmaceutical company's stock worth $15,959,000 after acquiring an additional 2,220 shares during the period. 76.05% of the stock is owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.